Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999

Pediatric Infectious Disease Journal

Volumn 22, Issue 7, 2003, Pages 635-641

  Selik, Richard M ^a   Lindegren, Mary Lou ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Cause of death; Child; Death certificates; Heart disease; Human immunodeficiency virus infections epidemiology; Human immunodeficiency virus infections mortality; Kidney disease; Liver disease; Opportunistic infections

Indexed keywords

ARTICLE; CACHEXIA; CHILD; CHILDHOOD MORTALITY; CYTOMEGALOVIRUS INFECTION; HEART DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MYCOBACTERIOSIS; NEWBORN; OPPORTUNISTIC INFECTION; PNEUMOCYSTOSIS; PRIORITY JOURNAL; UNITED STATES; VIRUS TRANSMISSION; WASTING SYNDROME;

ADOLESCENT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; DEATH CERTIFICATES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; POISSON DISTRIBUTION; PROBABILITY; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; UNITED STATES;

EID: 0041843861     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200307000-00013     Document Type: Article

References (41)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type-1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
2. Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994;43(RR-11):1-20.
3. Centers for Disease Control and Prevention. US Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR 1995;44(RR-7):1-15.
4. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral and revised recommendations for HIV screening of pregnant women. MMWR 2001;50 (RR-19):59-81.
5. Centers for Disease Control and Prevention. Success in implementing Public Health Service guidelines to reduce perinatal transmission of HIV: Louisiana, Michigan, New Jersey, and South Carolina, 1993, 1995, and 1996. MMWR 1998;47:688-91.
6. Centers for Disease Control and Prevention. Successful implementation of perinatal HIV prevention guidelines; a multistate surveillance evaluation. MMWR 2001;50(RR-6):17-28.
7. Lindegren ML, Steinberg S, Byers RH. Epidemiology of HIV/AIDS in children. Pediatr Clin North Am 2000;47:1-20,.
8. Centers for Disease Control and Prevention. Progress toward elimination of perinatal HIV infection: Michigan, 1993-2000. MMWR 2002;51:93-7.
9. Rutstein RM. Prevention of perinatal HIV infection. Curr Opin Pediatr 2001;13:408-16.
10. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484-94.
11. Frederick T, Thomas P, Mascola L, et al. Human immunodeficiency virus-infected adolescents: a descriptive study of older children in New York City, Los Angeles County, Massachusetts, and Washington, DC. Pediatr Infect Dis J 2000;19:551-5.
12. Lindegren ML, Byers R, Bertolli J, et al. Increasing numbers of adolescents living with perinatal HIV infection in the United States [Abstract TuPeC3351]. In: XIII International Conference on AIDS, Durban, South Africa, July 9 to 14, 2000. vol. 1:402-3.
13. Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002;29:378-87.
14. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999;18:682-9.
15. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet 2002;2:93-102.
16. Frederick T, Mascola L, Peters V, et al. Trends in HAART use and immune status among HIV-infected infants and children in the pediatric spectrum of HIV disease project, United States, 1994-2000 [Abstract TuPeC4735]. In: XIV International Conference on AIDS, Barcelona, Spain, July 7 to 12, 2002.
17. Israel RA, Rosenberg HM, Curtin LR. Analytical potential for multiple cause-of-death data. Am J Epidemiol 1986;124:161-79.
18. World Health Organization. International classification of diseases: manual of the international statistical classification of diseases, injuries, and causes of death. 9th revision. Geneva: World Health Organization, 1977.
19. World Health Organization. ICD-10: International statistical classification of diseases and related health problems. 10th revision. Geneva: World Health Organization, 1992.
20. Murphy SL. Deaths: final data for 1998. Nat Vital Stat Rep 2000;48:97.
21. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36 (Suppl 1S):3S-12S.
22. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43(RR-12):7-8.
23. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(RR-17):15.
24. SAS Institute, Inc. SAS/STAT user's guide. version 8. Cary, NC: SAS Institute Inc., 1999:1361-442.
25. Simonds RJ, Lindegren ML, Thomas P, et al. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. N Engl J Med 1995;332:786-90.
26. Centers for Disease Control and Prevention. 1995 Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995;44(RR-4):1-11.
27. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
28. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. AIDS 1999;13:1687-95.
29. Abrams EJ, Weedon J, Bertolli J, et al. Aging cohort of perinatally human immunodeficiency virus-infected children in New York City. Pediatr Infect Dis J 2001;20:511-17.
30. De Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000;248:2871-2.
31. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-54.
32. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-90.
33. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR 1998;47(RR-4):13-21.
34. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl 1):S5-14.
35. Thea DM, Lambert G, Weedon J, et al. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. Pediatrics 1996;97:59-64.
36. Maldonado YA, Araneta RG, Hersh AL. Pneumocystis carinii pneumonia prophylaxis and early clinical manifestations of severe perinatal human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 1998;17:398-402.
37. Centers for Disease Control and Prevention. AIDS among children: United States, 1996. MMWR 1996;45:1005-10.
38. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2001;13(No. 1):32. Available at: http://www.cdc.gov/hiv/stats/hasr1301/fig6.htm.
39. Lindegren ML, Byers RH Jr, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999;282:531-8.
40. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR 1998;47(RR-2):1-30 (guidelines updated February 4, 2002, available at http://hivatis.org/trtgdlns.html#Perinatal; accessed July 8, 2002).
41. Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J 2003;22:56-62.